Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CDKN2A as a uveal and cutaneous melanoma susceptibility gene.
Kannengiesser C, Avril MF, Spatz A, Laud K, Lenoir GM, Bressac-de-Paillerets B. Kannengiesser C, et al. Among authors: laud k. Genes Chromosomes Cancer. 2003 Nov;38(3):265-8. doi: 10.1002/gcc.10286. Genes Chromosomes Cancer. 2003. PMID: 14506702
Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma.
Laud K, Marian C, Avril MF, Barrois M, Chompret A, Goldstein AM, Tucker MA, Clark PA, Peters G, Chaudru V, Demenais F, Spatz A, Smith MW, Lenoir GM, Bressac-de Paillerets B; French Hereditary Melanoma Study Group. Laud K, et al. J Med Genet. 2006 Jan;43(1):39-47. doi: 10.1136/jmg.2005.033498. Epub 2005 Jun 3. J Med Genet. 2006. PMID: 15937071 Free PMC article.
BRAF as a melanoma susceptibility candidate gene?
Laud K, Kannengiesser C, Avril MF, Chompret A, Stoppa-Lyonnet D, Desjardins L, Eychene A, Demenais F, Lenoir GM, Bressac-de Paillerets B; French Herediatary Melanoma Study Group. Laud K, et al. Cancer Res. 2003 Jun 15;63(12):3061-5. Cancer Res. 2003. PMID: 12810628
Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countries.
Goldstein AM, Chaudru V, Ghiorzo P, Badenas C, Malvehy J, Pastorino L, Laud K, Hulley B, Avril MF, Puig-Butille JA, Miniere A, Marti R, Chompret A, Cuellar F, Kolm I, Mila M, Tucker MA, Demenais F, Bianchi-Scarra G, Puig S, de-Paillerets BB. Goldstein AM, et al. Among authors: laud k. Int J Cancer. 2007 Aug 15;121(4):825-31. doi: 10.1002/ijc.22712. Int J Cancer. 2007. PMID: 17397031 Free article.
Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma.
Postel-Vinay S, Véron AS, Tirode F, Pierron G, Reynaud S, Kovar H, Oberlin O, Lapouble E, Ballet S, Lucchesi C, Kontny U, González-Neira A, Picci P, Alonso J, Patino-Garcia A, de Paillerets BB, Laud K, Dina C, Froguel P, Clavel-Chapelon F, Doz F, Michon J, Chanock SJ, Thomas G, Cox DG, Delattre O. Postel-Vinay S, et al. Among authors: laud k. Nat Genet. 2012 Feb 12;44(3):323-7. doi: 10.1038/ng.1085. Nat Genet. 2012. PMID: 22327514
Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients.
Odri GA, Dumoucel S, Picarda G, Battaglia S, Lamoureux F, Corradini N, Rousseau J, Tirode F, Laud K, Delattre O, Gouin F, Heymann D, Redini F. Odri GA, et al. Among authors: laud k. Cancer Res. 2010 Oct 1;70(19):7610-9. doi: 10.1158/0008-5472.CAN-09-4272. Epub 2010 Sep 14. Cancer Res. 2010. PMID: 20841471
Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
Picarda G, Lamoureux F, Geffroy L, Delepine P, Montier T, Laud K, Tirode F, Delattre O, Heymann D, Rédini F. Picarda G, et al. Among authors: laud k. Clin Cancer Res. 2010 Apr 15;16(8):2363-74. doi: 10.1158/1078-0432.CCR-09-1779. Epub 2010 Apr 6. Clin Cancer Res. 2010. PMID: 20371692 Free article.
39 results